To establish whether inhibition of RORα activity would affect TH17 cells derived from patients with IBD, specifically Ulcerative Colitis (UC), we differentiated naïve CD4+ T cells from PBMCs from UC patients vs. healthy, age-matched controls (HC) under conditions described in Fig. 8a. This evidence concerns the gene CD4 and inflammatory bowel disease.